Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Art & Psychiatry
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Conference Oration
Conference Summary
Continuing Medical Education
Cosmetic Dermatology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
Editor Speaks
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Miscellaneous Letter
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News & Views
Observation Letter
Observation Letters
Original Article
Original Contributions
Pattern of Skin Diseases
Pediatric Dermatology
Pediatric Rounds
Presedential Address
Presidential Address
Presidents Remarks
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Study Letter
Study Letters
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapy Letter
Therapy Letters
View Point
What’s new in Dermatology
View/Download PDF

Translate this page into:

Case Letter

Dupilumab use in non-atopic chronic hand eczema: Two cases and a review of the literature

Department of Dermatology, Peking University People’s Hospital, Beijing, China
Corresponding author: Jianzhong Zhang, Department of Dermatology, Peking University People’s Hospital, Beijing, China.
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Li T, Li H, Zhang J. Dupilumab use in non-atopic chronic hand eczema: Two cases and a review of the literature. Indian J Dermatol Venereol Leprol doi: 10.25259/IJDVL_721_2022


Chronic hand eczema (CHE) is a common inflammatory disease that seriously affects people’s quality of life. Chronic eczema is generally resistant to topical treatment, dupilumab has been found to be effective in few cases of hand eczema with associated atopic dermatitis. We report two cases of non-atopic CHE who are successfully treated with dupilumab.

Case 1: A 57-year-old man presented to the dermatology clinic with a 1-year history of dry, fissured, scaling eruptions on the fingertips and palms, accompanied by minor itching. He had received multiple treatments including potent topical corticosteroids and tacrolimus but with little improvement. On physical examination, his fingertips and palms exhibited dry, fissured and scaly plaques without any vesicles [Figure 1a]. Laboratory studies and the patch test showed no positive results. Due to the absence of a history of allergic disorders, non-atopic hyperkeratotic CHE was diagnosed but the underlying aetiology remained unknown. Traditionally, oral retinoids or immunosuppressive agents are administered when the topical therapy is inadequate. However, given the safety profile, the patient preferred a biological agent so he received a 600 mg injection of dupilumab as a loading dose and 300 mg injection every 2 weeks thereafter. Surprisingly, his persistent lesions improved completely after 3 months [Figure 1b]. The dermatology life quality index score decreased from 11.9 points at baseline to 3.6 points 3 months later. The treatment was well tolerated and no side effect was observed.

Case 2: A 58-year-old woman presented with a 20-year history of progressive desquamative and fissured eruption on her fingertips [Figure 2a], accompanied by minor pain. There were no vesicles and no rashes on any other part of the body. She had received potent corticosteroids and tacrolimus under occlusion but the effect was poor. No allergen was detected through the patch test. Similar to case 1, she had no history of atopy and non-atopic hyperkeratotic CHE was diagnosed. After consulting with the patient, she chose a biological agent over a conventional topical treatment. The treatment of dupilumab was initiated with 600 mg subcutaneously on day 1 followed by 300 mg subcutaneously every 14 days. Her response was so impressive that a 90% improvement was observed in just 2 weeks, and she completely recovered in 6 weeks [Figure 2b]. Six weeks later, the dermatology life quality index score decreased from 10.7 points at baseline to 4.8 points. No adverse events were reported and the response was maintained until the time of writing.

Figure 1a:: Case 1 at baseline
Figure 1b:: Case 1 after 12 weeks of treatment
Figure 2a:: Case 2 at baseline
Figure 2b:: Case 2 after 6 weeks of treatment

Dupilumab, a fully human monoclonal antibody that blocks IL-4 and IL-13, is proven for the treatment of atopic dermatitis. CHE is a potential new indication for dupilumab since numerous studies have shown remarkable effects in CHE patients with atopy.1

We found only five previous reports of non-atopic patients with persistent CHE treated with dupilumab [Table 1].24 All of the seven cases including ours were treated with dupilumab at standard FDA-approved dosing, and the lesions of six cases were almost cleared in 4–16 weeks. Only one case had little improvement, which may be caused by continuous occupational exposure to irritants and friction. Crepy et al.5 reported a similar case in which an atopic CHE with documented occupational exposure had a poor response to dupilumab.

Table 1:: Published and our cases of non-atopic CHE treated with dupilumab
Case Sex, age Clinical pattern and severity History of atopy Patch test Disease duration Previous therapy Response to dupilumab Adverse events
Halling et al., 2020 M, 67 Vesicular CHE, severe No 3 years tCS, Pho, Mtx, Azt, CsA Almost clear in 4 weeks N/S
Zhu et al., 2020 M, 43 Hyperkeratotic CHE, severe No 5 years tCS, Pho, alitretinoin, Mtx, CS Almost clear in 4 weeks N/S
Loman et al., 2021 M, 65 Hyperkeratotic CHE, moderate No 4 years tCS, Mtx, alitretinoin Only improvement of itch in 16 weeks N/S
M, 47 Hyperkeratotic CHE, severe No 9 years tCS, Mtx, alitretinoin, CsA Almost clear in 16 weeks N/S
F, 65 Hyperkeratotic CHE, severe No 4 years tCS, Azt, alitretinoin Almost clear in 16 weeks N/S
Our cases M, 57 Hyperkeratotic CHE, severe No 1 year tCS, topical tacrolimus Almost clear in 12 weeks None
F, 58 Hyperkeratotic CHE, severe No 20 years tCS, topical tacrolimus Almost clear in 6 weeks None

tCS, topical corticosteroids; Pho, phototherapy; Mtx, methotrexate; Azt, azathioprine; CsA, cyclosporine; N/S, not significant

In conclusion, we have described two cases that strengthen the evidence that dupilumab’s efficacy in non-atopic CHE is equally promising. In addition, based on the scientific evidence, those with continuous occupational exposure may have a limited response to dupilumab whether they were of atopic or not.

Declaration of patient consent

Patient’s consent not required as patient’s identity is not disclosed or compromised.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


  1. , , , . The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis—52 week results from the Dutch BioDay Registry. Contact Dermatitis. 2022;87:185-91.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , . Severe treatment-resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab. Contact Dermatitis. 2020;83:37-8.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , . Dupilumab for occupational irritant hand dermatitis in a nonatopic individual: A case report. JAAD Case Rep. 2020;6:296-8.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , . Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab. Contact Dermatitis. 2021;84:124-7.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , , . Blocking type 2 inflammation by dupilumab does not control classic (type 1-driven) allergic contact dermatitis in chronic hand eczema. Contact Dermatitis. 2019;81:145-7.
    [CrossRef] [PubMed] [Google Scholar]

Fulltext Views

PDF downloads
View/Download PDF
Download Citations
Show Sections